AGC Pharma Chemicals
AGC Pharma Chemicals is a CDMO subsidiary of AGC Inc. specializing in small molecule APIs and intermediates, with expertise in fluorinated substances and HPAPI manufacturing. It serves pharmaceutical and biotech companies globally with integrated development and manufacturing services from gram to ton scale.
- Company typePrivate
- Founded2019
- HeadquartersMalgrat De Mar, Spain
- Headcount101–250
- GTM typeB2B
- OfferingServices
What AGC Pharma Chemicals does
AGC Pharma Chemicals is a Contract Development and Manufacturing Organization (CDMO) specializing in small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, with particular expertise in fluorinated substances. The company operates production facilities in Malgrat de Mar (Barcelona), Spain — its European headquarters — and in Japan, offering integrated end-to-end services spanning gram-scale laboratory work through ton-scale commercial manufacturing. It serves pharmaceutical and biotech companies requiring API development and manufacturing support across the full drug lifecycle, including process development, API lifecycle management, quality management, supply chain management, and cGMP manufacturing.
The company's product portfolio comprises six generic APIs for human pharmaceuticals (Mexiletine Hydrochloride, Gliquidone, Dipyridamole, Telmisartan, Pirenzepine) and one for animal health (Pimobendan), alongside fluorinated raw materials and specialized CDMO service lines. Manufacturing capabilities include a micronization plant with 30 kg/h (max 50 kg/h) processing capacity using Hosokawa Alpine Multi-Mill technology capable of handling OEB 4 high-potency APIs, a GMP Kilo Lab for HAPI production up to 7 kg with Hastelloy reactors, and a new 7,500 m³ HPAPI facility under construction. AGC Pharma Chemicals was the first CDMO in Spain to implement a fully integrated Electronic Batch Record (eBR) system connected to its Distributed Control System (DCS).
AGC Pharma Chemicals is a wholly-owned subsidiary of AGC Inc. (formerly Asahi Glass Company), a Japanese multinational conglomerate reporting approximately EUR 12.7 billion in net sales in 2021. The company generates revenue through B2B professional services for custom API development and manufacturing projects on a quote-based engagement model, reaching customers via enterprise field sales, participation in major pharmaceutical industry events (CPHI, BIO, DCAT Week, BOS, BioTrinity, Swiss Biotech Day), and strategic partnerships such as its 2023 alliance with UK-based CRO CatSci Ltd. The business transitioned in 2019 from a single-customer production center to a multi-client CDMO, and is currently executing a EUR 90 million Barcelona HPAPI facility expansion announced in 2022 that is expected to create approximately 100 new jobs.
AGC Pharma Chemicals firmographics
Firmographics- Name
- AGC Pharma Chemicals
- Legal name
- AGC Pharma Chemicals Europe S.L.U.
- Website
- https://agcpharmachemicals.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AGC Pharma Chemicals is a CDMO subsidiary of AGC Inc. specializing in small molecule APIs and intermediates, with expertise in fluorinated substances and HPAPI manufacturing. It serves pharmaceutical and biotech companies globally with integrated development and manufacturing services from gram to ton scale.
- Ownership category
- akta.pro rank
AGC Pharma Chemicals industry classification
Industry- Product category
- Pharmaceutical CDMO Services (Contract API Manufacturing)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where AGC Pharma Chemicals is headquartered
LocationHeadquarters
- HQ city
- Malgrat De Mar
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
AGC Pharma Chemicals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- CDMO Services - API Manufacturing: AGC Pharma Chemicals generates revenue through providing contract development and manufacturing services for Active Pharmaceutical Ingredients (APIs) and intermediates. Services span from early-phase clinical trial material manufacturing through commercial-scale production, covering the full API lifecycle.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
AGC Pharma Chemicals product offering
Product offeringCore offering
AGC Pharma Chemicals is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates on a contract basis. The company delivers integrated end-to-end solutions spanning process development, scale-up, cGMP commercial manufacturing, micronization, HPAPI production, quality management, and supply chain management, supported by facilities in Spain and Japan. It also maintains a catalog of off-patent generic APIs and fluorinated raw materials offered directly.
Product overview
AGC Pharma Chemicals is a Contract Development and Manufacturing Organization (CDMO) specializing in small molecule Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates a unified manufacturing platform with production facilities in Spain and Japan, offering integrated CDMO services from early-phase clinical development through commercial-scale manufacturing. Their product portfolio includes six generic APIs for human pharmaceuticals (Mexiletine Hydrochloride, Gliquidone, Dipyridamole, Telmisartan, Pirenzepine) and one for animal health (Pimobendan), plus fluorinated raw materials. Service offerings encompass Process Development, API Life Cycle Management, Quality Management, Supply Chain Management, and cGMP Manufacturing. Manufacturing capabilities include a state-of-the-art micronization plant (OEB 4 capable), a GMP Kilo Lab for HAPI production up to 7 kg scale, and a major HPAPI facility expansion in Barcelona. The company emphasizes expertise in fluorinated substances and maintains over 20 years without FDA 483 observations.
Differentiator
Problem solved
Functional benefit
Products and services
- Mexiletine Hydrochloride
Quantifiable outcome
- 20+ years without FDA 483 observations
- +3 more outcomes
Companies that use AGC Pharma Chemicals
Customer profileSegments3 records
Ideal customer profiles3 records
AGC Pharma Chemicals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AGC Pharma Chemicals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Pharmaceutical Supply Chain Initiative (PSCI)minorAGC Pharma Chemicals joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. PSCI is a pharmaceutical industry initiative focused on improving supply chain sustainability, responsibility, and efficiency across the pharmaceutical sector.
- AbilityPharmaminorCollaboration between AGC Pharma Chemicals and AbilityPharma for the production of an innovative pancreatic cancer treatment. The partnership combines expertise and experience from both companies to advance a novel cancer therapy through clinical development and toward commercialization.
- CatSci LtdcoreStrategic alliance between AGC Pharma Chemicals (CDMO) and CatSci Ltd (CRO) providing customers with comprehensive services from preclinical to clinical phases. CatSci, based in Cardiff, Wales, UK, offers early-phase API development services including chemical and analytical development, crystallization programs for solid forms, preformulation studies, and HPAPI development. The partnership enables optimal and agile technology transfer to AGC's production facilities, covering CMC activities from gram to ton scale manufacturing for clinical through commercial production.
Scale indicators9 records
Recent moves10 records
Expansion highlights5 records
AGC Pharma Chemicals competitors and assessment
Company assessmentBroad incumbents
- Lonza: Swiss-headquartered global CDMO leader offering small-molecule APIs, biologics, and cell & gene services. Comparable to AGC as a small-molecule API/intermediates CDMO serving large pharma, but materially larger and broader in scope.
Direct peers
- Curia (formerly Albany Molecular Research): US-headquartered CDMO providing small-molecule API development, manufacturing, and analytical services. Comparable to AGC in early-phase to commercial CDMO scope for small molecules, with broader finished-dose capabilities.
- Axplora (formerly Novasep): European CDMO providing APIs, intermediates, HPAPI, and chromatography services. Comparable to AGC in small-molecule API CDMO services, HPAPI capabilities, and European manufacturing footprint.
- Hovione: Portugal-based privately held CDMO specializing in small-molecule APIs, particle engineering, and HPAPI capabilities. Highly comparable to AGC in scale, scope, geographic profile (Europe), and HPAPI/containment capabilities.
- Siegfried Holding: Swiss-listed CDMO offering small-molecule API manufacturing and finished dosage forms. Comparable to AGC in API/intermediates CDMO services for global pharma, with broader finished-dose capabilities.
- WuXi STA (WuXi AppTec): China-based CDMO specializing in small-molecule APIs, intermediates, and preformulation. Directly comparable on small-molecule API CDMO services and scale-up/commercial manufacturing for pharma and biotech customers.
- EuroAPI: European API manufacturer spun out of Sanofi, offering small-molecule APIs and CDMO services. Directly comparable to AGC in active substance manufacturing, regulatory footprint, and European customer base.
- Cambrex: US-headquartered CDMO focused on small-molecule APIs, intermediates, and finished dosage forms. Closely comparable to AGC in target customers, service breadth, and scale across clinical and commercial API manufacturing.
- Recipharm: European CDMO focused on small-molecule APIs, sterile fill-finish, and solid dosage forms. Comparable to AGC on European small-molecule CDMO positioning and target customer base.
Regional players
- Ajinomoto Bio-Pharma Services: Japanese CDMO offering small-molecule and biologic manufacturing services. Comparable to AGC as a Japanese-origin pharma CDMO serving global customers, with overlapping small-molecule API capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
AGC Pharma Chemicals social profiles
Digital presenceAGC Pharma Chemicals financial estimates
Financial estimateRevenue estimate
Valuation estimate
AGC Pharma Chemicals leadership team
Management profileNumber of profiles
Profiles5 records
AGC Pharma Chemicals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AGC Pharma Chemicals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AGC Pharma Chemicals
What does AGC Pharma Chemicals do?
AGC Pharma Chemicals is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates on a contract basis. The company delivers integrated end-to-end solutions spanning process development, scale-up, cGMP commercial manufacturing, micronization, HPAPI production, quality management, and supply chain management, supported by facilities in Spain and Japan. It also maintains a catalog of off-patent generic APIs and fluorinated raw materials offered directly.
Is AGC Pharma Chemicals a public or private company?
AGC Pharma Chemicals is a private company. It is classified as corporate owned and is currently operating.
When was AGC Pharma Chemicals founded?
AGC Pharma Chemicals was founded in 2019. It employs 101 to 250 people.
Where is AGC Pharma Chemicals based?
AGC Pharma Chemicals is headquartered in Malgrat De Mar, Spain, in the Europe region.
How does AGC Pharma Chemicals make money?
One revenue line is on record: CDMO Services - API Manufacturing.
Who are AGC Pharma Chemicals's main competitors?
Lonza is listed as a broad incumbent. Direct peers are Curia (formerly Albany Molecular Research), Axplora (formerly Novasep), Hovione, Siegfried Holding, WuXi STA (WuXi AppTec), EuroAPI, Cambrex and Recipharm. Ajinomoto Bio-Pharma Services is listed as a regional player.
Does AGC Pharma Chemicals have an API?
No public API is recorded for AGC Pharma Chemicals.
What industry is AGC Pharma Chemicals in?
AGC Pharma Chemicals's product category is Pharmaceutical CDMO Services (Contract API Manufacturing). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 3254 and its SIC code is 2834.